National Pension Service boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 12.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 758,088 shares of the company’s stock after purchasing an additional 82,222 shares during the period. National Pension Service owned approximately 0.07% of Eli Lilly and worth $62,694,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of LLY. Heritage Trust Co purchased a new position in Eli Lilly and during the 1st quarter worth $135,000. Point72 Asia Hong Kong Ltd lifted its stake in shares of Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after acquiring an additional 1,239 shares during the period. Penserra Capital Management LLC lifted its stake in shares of Eli Lilly and by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after acquiring an additional 176 shares during the period. American National Bank lifted its stake in shares of Eli Lilly and by 5.2% in the 2nd quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after acquiring an additional 104 shares during the period. Finally, Sandy Spring Bank lifted its stake in shares of Eli Lilly and by 51.8% in the 1st quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after acquiring an additional 750 shares during the period. 75.72% of the stock is currently owned by institutional investors.
Eli Lilly and Company (NYSE LLY) traded up 0.64% on Friday, hitting $85.54. 3,506,102 shares of the stock were exchanged. The company has a market cap of $90.24 billion, a P/E ratio of 37.01 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The company’s 50 day moving average price is $80.84 and its 200-day moving average price is $82.02.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period in the previous year, the firm earned $0.86 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “National Pension Service Buys 82,222 Shares of Eli Lilly and Company (LLY)” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://stocknewstimes.com/2017/10/01/national-pension-service-has-62-69-million-position-in-eli-lilly-and-company-lly.html.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 590,000 shares of company stock worth $48,551,300. Insiders own 0.20% of the company’s stock.
Several research firms have recently commented on LLY. BMO Capital Markets restated a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Leerink Swann cut shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $93.00 to $90.00 in a research note on Wednesday, July 26th. BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Finally, UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a research note on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $88.27.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.